HI
IBRX icon

Harbour Investments’s ImmunityBio IBRX Stock Holding History

Harbour Investments’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
1,311
– – ﹤0.01% 3280
2026
Q1 		$10.1K Sell
1,311
-3,149
-71% -$21.6K ﹤0.01% 3260
2025
Q4 		$8.83K Buy
4,460
+3,460
+346% +$7.84K ﹤0.01% 2798
2025
Q3 		$2.46K Hold
1,000
– – ﹤0.01% 3221
2025
Q2 		$2.64K Buy
+1,000
New +$2.69K ﹤0.01% 3055
2021
Q4 		– Sell
-1,301
Closed -$13K – 3123
2021
Q3 		$13K Buy
1,301
+1
+0.1% +$11 ﹤0.01% 2527
2021
Q2 		$19K Hold
1,300
– – ﹤0.01% 2370
2021
Q1 		$31K Buy
+1,300
New +$33.7K ﹤0.01% 1950

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbour Investments's IBRX Position: Q2 2026 in Review

Harbour Investments held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,311 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Harbour Investments first reported a position in IBRX in Q1 2021 and has held it in 8 quarters since. The position peaked at $31K in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Harbour Investments held 1,311 shares of ImmunityBio worth $11.5K as of Q2 2026.
  • Harbour Investments left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3280 holding.
  • Harbour Investments first reported a position in ImmunityBio in Q1 2021 and has held it in 8 quarters since.
  • Harbour Investments's ImmunityBio position peaked at $31K in Q1 2021.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.